AbbVie at ACT 2026

Nov 15–18, 2026 San Antonio, TX ~1.4k attendees Website

AbbVie takes part in 4 sessions at ACT 2026 in San Antonio. Its program covers testing a drug's potential for abuse ahead of a marketing application and a case study on detecting and controlling mouse parvovirus during a general toxicity study. It also introduces the meeting's Hot Topics segment.

Organization	ACT 2026 Attendance
AbbVie North Chicago, IL
abbvie.com Pharmaceutical companies Global biopharmaceutical company that discovers, develops and markets medicines in immunology, oncology, neuroscience and aesthetics.	Poster Mon Nov 16 5:00pm–6:30pm Mouse Parvovirus Detection and Control on a General Toxicity Study: A Case Study (P130) Nelson Exhibit Ballroom · Poster P130 Animal models Talk Tue Nov 17 9:55am–10:15am Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09) Abuse Liability Assessment (S09-4) Safety pharmacology Session Wed Nov 18 2:00pm–5:00pm Hot Topics (S18) with U.S. Food and Drug Administration 2:00pmIntroduction (S18-1)U.S. Food and Drug Administration, AbbVie 2:05pmCross-Industry Survey of Nonclinical Development Strategies for Oligonucleotide Therapeutics: Species Selection, Dose Setting, and Translational Approaches (S18-2)Novartis 2:30pmBenchmark Dose Modeling: Advancing Transparency and Next-Generation Applications in Risk Assessment (S18-3)HESI 2:55pmEmerging Insights on QTc Risks in Targeted Protein Degraders (S18-4)HESI 3:45pmWinning the Rat Race: Repurposing GLP-1 Receptor Agonists for Addiction (S18-5)National Institutes of Health 4:15pmFDA Forensic Investigations of Product Adulteration (S18-6)U.S. Food and Drug Administration Talk Wed Nov 18 2:00pm–2:05pm Part of Hot Topics (S18) Introduction (S18-1) with U.S. Food and Drug Administration

Organization

ACT 2026 Attendance

AbbVie

North Chicago, IL

abbvie.com

Pharmaceutical companies

Global biopharmaceutical company that discovers, develops and markets medicines in immunology, oncology, neuroscience and aesthetics.

Poster

Mon Nov 16
5:00pm–6:30pm

Mouse Parvovirus Detection and Control on a General Toxicity Study: A Case Study (P130)

Nelson Exhibit Ballroom · Poster P130

Animal models

Talk

Tue Nov 17
9:55am–10:15am

Part of What Did You Forget on Your Way to Your NDA/MAA? Strategic Considerations for Late-Stage Nonclinical Safety Studies (S09)

Abuse Liability Assessment (S09-4)

Safety pharmacology

Session

Wed Nov 18
2:00pm–5:00pm

Hot Topics (S18)

with U.S. Food and Drug Administration

2:00pmIntroduction (S18-1)U.S. Food and Drug Administration, AbbVie
2:05pmCross-Industry Survey of Nonclinical Development Strategies for Oligonucleotide Therapeutics: Species Selection, Dose Setting, and Translational Approaches (S18-2)Novartis
2:30pmBenchmark Dose Modeling: Advancing Transparency and Next-Generation Applications in Risk Assessment (S18-3)HESI
2:55pmEmerging Insights on QTc Risks in Targeted Protein Degraders (S18-4)HESI
3:45pmWinning the Rat Race: Repurposing GLP-1 Receptor Agonists for Addiction (S18-5)National Institutes of Health
4:15pmFDA Forensic Investigations of Product Adulteration (S18-6)U.S. Food and Drug Administration

Talk

Wed Nov 18
2:00pm–2:05pm

Part of Hot Topics (S18)

Introduction (S18-1)

with U.S. Food and Drug Administration

Instantly find 20 buyers from AbbVie

Get a list of who you should contact, their contact info, and what to say.

Totally free and instant, no sign up necessary!

Not affiliated with or endorsed by the American College of Toxicology (ACT). Organization details are derived from ACT’s published program, exhibitor floor plan and supporter list, and each organization’s own website. Submit a correction